Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
• Diagnosis of a relapsed/refractory hematologic malignancy
• Age ≥ 18 years
• Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
• Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
• Patient resides within catchment served by Care Dimensions Hospice
• Physician-estimated prognosis of six months or less
• Identified informal caregiver of enrolled patient with hematologic malignancy
• Age ≥ 18 years